Advertisement
Advertisement
U.S. Markets open in 1 hr 2 mins
Advertisement
Advertisement
Advertisement
Advertisement

Tenax Therapeutics, Inc. (TENX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.1815-0.0084 (-4.42%)
At close: 04:00PM EDT
0.1815 0.00 (0.00%)
Pre-Market: 08:05AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close0.1899
Open0.1899
Bid0.1815 x 800
Ask0.1969 x 1400
Day's Range0.1800 - 0.2002
52 Week Range0.1500 - 1.9000
Volume326,306
Avg. Volume440,034
Market Cap5.441M
Beta (5Y Monthly)2.09
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for TENX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Tenax Therapeutics, Inc.
    Analyst Report: Lilly(Eli) & CoEli Lilly, based in Indianapolis, develops and manufactures therapies to treat pain, diabetes, cancer, and neurodegenerative diseases. The shares are a component of the S&P 500.
    Rating
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • GlobeNewswire

    Tenax Therapeutics Announces the Evaluation of Strategic Alternatives

    MORRISVILLE, N.C., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the Company is evaluating alternative strategic paths focused on maximizing shareholder value. Roth Capital Partners will support Tenax Therapeutics as its financial advisor in this process. Tenax Therape

  • Zacks Small Cap Research

    TENX: The Pressure’s On: Awaiting Phase 3 Start

    By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT 2Q:22 Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported second quarter 2022 results on August 11, 2022 via its filing of Form 10-Q with the SEC. Since our previous report, the company announced the completion of its pharmacokinetic study of TNX-201 and held a key opinion leader (KOL) event on

  • Business Wire

    Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH)

    MORRISVILLE, N.C., May 25, 2022--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will host a key opinion leader (KOL) webinar about TNX-201 (oral, modified release imatinib), in development as a potential treatment for pulmonary arterial hypertension (PAH), on Thursday, June 2, 2022 at 11:00am Eastern

Advertisement
Advertisement